Drugs / Urelumab
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials · 1 met primary | ||||||
| Phase 1 | NCT03431948 | Mar 2018 → Feb 2020 | cancer | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT02658981 | Aug 2016 → Apr 2022 | gliosarcoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Met primary |
| Phase 1 | NCT02534506 | Nov 2015 → Nov 2016 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02252263 | Dec 2014 → Oct 2017 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02110082 | Apr 2014 → Dec 2016 | colorectal cancer, head and neck cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01775631 | Mar 2013 → Aug 2016 | B-cell neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01471210 | Feb 2012 → Apr 2016 | B-cell non-Hodgkin lymphoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00461110 | Jan 2008 → Apr 2009 | non-small cell lung carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT00351325 | Sep 2007 → Mar 2009 | high grade malignant neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03792724 | Jan 2019 → Jan 2023 | neoplasm | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase 1/2 | NCT02253992 | Sep 2014 → May 2019 | B-cell non-Hodgkin lymphoma, cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/2 | NCT00309023 | Dec 2005 → Dec 2008 | neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02845323 | May 2017 → Jul 2027 expected | urinary bladder cancer, urothelial carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02451982 | Mar 2016 → Sep 2026 overdue | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | Met primary |
| Phase 2 | NCT02420938 | Jul 2015 → Jul 2020 | leukemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT02652455 Background | Mar 2016 → Aug 2020 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00612664 Comparator | Mar 2008 → Oct 2009 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-11-12 | Bristol-Myers Squibb | Results Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma bms.com ↗
The combination of urelumab and Opdivo showed encouraging efficacy among 46 evaluable melanoma patients with an objective response rate (ORR) of 50% (23/46 with 18 confirmed and 5 unconfirmed). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-11-12 | Bristol-Myers Squibb | Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma bms.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Urelumab | “Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS” NCT02658981 ↗ |
| Known as | BMS-663513 | “A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors” NCT02534506 ↗8“Urelumab (BMS-663513) solution administered intravenously on specified days” NCT01471210 ↗ “Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS” NCT02658981 ↗ “Urelumab (BMS-663513) flat dose intravenous infusion on specified days” NCT01775631 ↗ “BMS-663513” NCT02652455 ↗ |
| Action | Activate | “Agonistic Anti-CD137” NCT00351325 ↗ |
| Modality | Monoclonal antibody | “an Agonistic Anti-CD137 Monoclonal Antibody” NCT00351325 ↗ |
| Route | Intravenous | “mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks” NCT00461110 ↗ |
| Target | TNFRSF9 | “anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab)” NCT02658981 ↗ |